David Smith has joined Galapagos as chief financial officer, the Belgium-based company said today.
The appointment takes effect Feb. 1, 2006.
Smith joins Galapagos after eight years with AstraZeneca Netherlands. Vicky Gwosdz, currently head of finance of Galapagos, will continue as controller.
Smith also trained as a chartered accountant with Coopers & Lybrand, Leeds. He has a degree in molecular biophysics from the University of Leeds.
Kenneth L. Horton has been appointed executive vice-president and general counsel for MDS, the company said yesterday. He will join MDS at the start of December.
Horton was vice-president and general counsel for the Life and Analytical Sciences business unit of PerkinElmer prior to this appointment. He practiced corporate law with Boston's Ropes and Gray and a strategy consultant in the U.S. and Europe.
He has a J.D. from Harvard Law School and an A.B. from Dartmouth College.
Sigma-Aldrich's board of directors elected Avi Nash as a director, the company said yesterday.
Nash currently heads a management consulting firm, Avi Nash LLC, launched in 2003. Prior to this, he was a partner at Goldman Sachs. He has worked at Booz, Allen & Hamilton and UOP.
Outgoing chief executive officer David Harvey made the announcement.
The board also appointed Jai Nagarkatti, president and chief operating officer of the company since 2004, as president and chief executive officer to replace Harvey, who will remain chairman of the board.
Also elected to the board, Nagarkatti's appointment takes effect on Jan. 1, 2006.
Nagarkatti has been with Sigma-Aldrich for 29 years in R&D, production, operations and sales and marketing. He has a Master's degree in chemistry from Osmania University in Hyderabad, India, and a Ph.D. in organic chemistry from Texas A&M University.
Samir Kaul is now a partner at Flagship Ventures, the firm said yesterday.
Kaul is the founding-chief-executive-officer of Codon Devices and co-founder of Helicos BioSciences. He was also a co-founder and startup president of Epitome Biosystems, where he remains on the board. He played an active role in other Flagship companies, including BG Medicine, Genstruct, and Morphotek.
Previously, he worked at the Institute for Genomic Research and was chairperson of the Arabidopsis Genome Initiative.
Michael Milburn has joined Metabolon as its chief scientific officer, the company said yesterday.
Prior to Metabolon, Milburn was senior vice-president of research and corporate development at Sirtris Pharmaceuticals. He was also senior vice-president of research at Plexxikon and held positions at Structural Genomix and GlaxoSmithKline.
He received his Ph.D. in structural chemistry at the University of California, Berkeley, and was a research fellow at Harvard Medical School.
Hybrigenics named Rémi Delansorne as the new chief executive officer of the company yesterday.
Delansorne has been vice-president for R&D since 2004. Prior to Hybrigenics, he headed global research on diabetes at Merck KGaA in 2002 and worked with Monaco's Theramex. He has a doctorate in veterinary medicine from the Alfort Veterinary School.
The company also named Daan J. Ellens as chairman of its Board of Directors.
Ellens has his own biotechnology consultancy firm, Elkerim, and was the chief executive officer of RheinBiotech prior to its IPO and 2002 merger with Bema Biotech. He has a PhD in molecular biology from the State University of Utrecht and an MBA from the University of Eindhoven.
The appointments follow the death earlier this year of Bart Kwist, president and CEO.
Beckman Coulter has named Arnold A. Pinkston as senior vice president, general counsel, and secretary, the company said earlier this week.
The vice-president and counsel appointments are effective Nov. 15, 2005. The secretary appointment is effective Dec. 1, pending Board approval. Pinkston will succeed William H. May, who is retiring.
Most recently, Pinkston was deputy general counsel for Lilly USA, part of the Eli Lilly Corporation. He currently serves on the Board of Directors of St. Vincent Health and Southwest Autism Research Center.
TekCel, a Magellan Biosciences company, named Elise Williams as vice president of sales and marketing this week.
Williams comes to TekCel from Matrix Technologies, where she worked for 15 years in a number of positions: sales representative, national sales manager, director of OEM sales.
Janet Woodcock, Deputy Commissioner of Operations and Chief Operating Officer at the U.S. Food and Drug Administration accepted the first Leadership in Personalized Medicine Award from the Personalized Medicine Coalition on Nov. 3 during a reception at the Harvard-Partners Center for Genetics and Genomics conference in Boston, MA.
"Through her determined initiative to introduce pharmacogenomics into the drug approval process, Dr. Woodcock has linked innovation to regulation in an effort to bring safer and more effective drugs to the American public," said PMC's executive director Edward Abrahams in a statement.